Molecule Information
General Information of the Molecule (ID: Mol01913)
| Name |
Bromodomain containing 2 (BRD2)
,Homo sapiens
|
||||
|---|---|---|---|---|---|
| Synonyms |
BRD2; KIAA9001; RING3
Click to Show/Hide
|
||||
| Molecule Type |
Protein
|
||||
| Gene Name |
BRD2
|
||||
| Gene ID | |||||
| Location |
chr6:32,968,594-32,981,505[+]
|
||||
| Sequence |
MLQNVTPHNKLPGEGNAGLLGLGPEAAAPGKRIRKPSLLYEGFESPTMASVPALQLTPAN
PPPPEVSNPKKPGRVTNQLQYLHKVVMKALWKHQFAWPFRQPVDAVKLGLPDYHKIIKQP MDMGTIKRRLENNYYWAASECMQDFNTMFTNCYIYNKPTDDIVLMAQTLEKIFLQKVASM PQEEQELVVTIPKNSHKKGAKLAALQGSVTSAHQVPAVSSVSHTALYTPPPEIPTTVLNI PHPSVISSPLLKSLHSAGPPLLAVTAAPPAQPLAKKKGVKRKADTTTPTPTAILAPGSPA SPPGSLEPKAARLPPMRRESGRPIKPPRKDLPDSQQQHQSSKKGKLSEQLKHCNGILKEL LSKKHAAYAWPFYKPVDASALGLHDYHDIIKHPMDLSTVKRKMENRDYRDAQEFAADVRL MFSNCYKYNPPDHDVVAMARKLQDVFEFRYAKMPDEPLEPGPLPVSTAMPPGLAKSSSES SSEESSSESSSEEEEEEDEEDEEEEESESSDSEEERAHRLAELQEQLRAVHEQLAALSQG PISKPKRKREKKEKKKKRKAEKHRGRAGADEDDKGPRAPRPPQPKKSKKASGSGGGSAAL GPSGFGPSGGSGTKLPKKATKTAPPALPTGYDSEEEEESRPMSYDEKRQLSLDINKLPGE KLGRVVHIIQAREPSLRDSNPEEIEIDFETLKPSTLRELERYVLSCLRKKPRKPYTIKKP VGKTKEELALEKKRELEKRLQDVSGQLNSTKKPPKKANEKTESSSAQQVAVSRLSASSSS SDSSSSSSSSSSSDTSDSDSG Click to Show/Hide
|
||||
| 3D-structure |
|
||||
| Function |
May play a role in spermatogenesis or folliculogenesis (By similarity). Binds hyperacetylated chromatin and plays a role in the regulation of transcription, probably by chromatin remodeling. Regulates transcription of the CCND1 gene. Plays a role in nucleosome assembly.
Click to Show/Hide
|
||||
| Uniprot ID | |||||
| Ensembl ID | |||||
| HGNC ID | |||||
| Click to Show/Hide the Complete Species Lineage | |||||
Type(s) of Resistant Mechanism of This Molecule
Drug Resistance Data Categorized by Drug
Approved Drug(s)
1 drug(s) in total
| Drug Resistance Data Categorized by Their Corresponding Mechanisms | ||||
|
|
||||
| Disease Class: Lymphoblastic lymphoma [ICD-11: 2A70.0] | [1] | |||
| Resistant Disease | Lymphoblastic lymphoma [ICD-11: 2A70.0] | |||
| Resistant Drug | Doxorubicin | |||
| Molecule Alteration | Expression | Up-regulation |
||
| Experimental Note | Identified from the Human Clinical Data | |||
| Cell Pathway Regulation | RasGRP1/Ras/ERK signaling pathway | Activation | hsa04010 | |
| Cell apoptosis | Inhibition | hsa04210 | ||
| In Vitro Model | Jurkat cells | Pleural effusion | Homo sapiens (Human) | CVCL_0065 |
| SUP-T1 cells | Pleural effusion | Homo sapiens (Human) | CVCL_1714 | |
| MEK-293 cells | Blood vessel | Homo sapiens (Human) | N.A. | |
| In Vivo Model | BALB/C-nu/nu athymic nude mice model | Mus musculus | ||
| Experiment for Molecule Alteration |
sqRT-PCR; Western blot analysis | |||
| Experiment for Drug Resistance |
MTT assay; Flow cytometry assay | |||
| Mechanism Description | The expression of BRD2 was upregulated in drug-resistant adult T-LBL samples. Functional studies of BRD2 further demonstrated the critical role of BRD2. BRD2 induces drug resistance of T-LBL by activating the MEK/ERK/c-Myc signaling pathway. | |||
| Disease Class: Lymphoblastic lymphoma [ICD-11: 2A70.0] | [1] | |||
| Resistant Disease | Lymphoblastic lymphoma [ICD-11: 2A70.0] | |||
| Resistant Drug | Doxorubicin | |||
| Molecule Alteration | Expression | Up-regulation |
||
| Experimental Note | Identified from the Human Clinical Data | |||
| Cell Pathway Regulation | RasGRP1/Ras/ERK signaling pathway | Activation | hsa04010 | |
| Cell apoptosis | Inhibition | hsa04210 | ||
| In Vitro Model | Jurkat cells | Pleural effusion | Homo sapiens (Human) | CVCL_0065 |
| SUP-T1 cells | Pleural effusion | Homo sapiens (Human) | CVCL_1714 | |
| MEK-293 cells | Blood vessel | Homo sapiens (Human) | N.A. | |
| In Vivo Model | BALB/C-nu/nu athymic nude mice model | Mus musculus | ||
| Experiment for Molecule Alteration |
sqRT-PCR; Western blot analysis | |||
| Experiment for Drug Resistance |
MTT assay; Flow cytometry assay | |||
| Mechanism Description | The expression of BRD2 was upregulated in drug-resistant adult T-LBL samples. Functional studies of BRD2 further demonstrated the critical role of BRD2. BRD2 induces drug resistance of T-LBL by activating the MEK/ERK/c-Myc signaling pathway. | |||
References
If you find any error in data or bug in web service, please kindly report it to Dr. Sun and Dr. Yu.
